T. Rowe Price Associates
LGND icon

T. Rowe Price Associates’s Ligand Pharmaceuticals LGND Stock Holding History

T. Rowe Price Associates’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.77M Buy
23,901
+3,909
+20% +$773K ﹤0.01% 1438
2025
Q4 		$3.78M Buy
19,992
+1,077
+6% +$207K ﹤0.01% 1489
2025
Q3 		$3.35M Buy
18,915
+947
+5% +$141K ﹤0.01% 1524
2025
Q2 		$2.04M Buy
17,968
+1,660
+10% +$177K ﹤0.01% 1628
2025
Q1 		$1.72M Buy
16,308
+790
+5% +$89.3K ﹤0.01% 1680
2024
Q4 		$1.66M Buy
15,518
+1,781
+13% +$201K ﹤0.01% 1730
2024
Q3 		$1.38M Buy
13,737
+146
+1% +$14.7K ﹤0.01% 1821
2024
Q2 		$1.15M Buy
13,591
+599
+5% +$47.7K ﹤0.01% 1837
2024
Q1 		$951K Buy
12,992
+610
+5% +$45K ﹤0.01% 1934
2023
Q4 		$885K Buy
12,382
+860
+7% +$50.8K ﹤0.01% 1925
2023
Q3 		$692K Buy
11,522
+1,104
+11% +$72.7K ﹤0.01% 1964
2023
Q2 		$752K Buy
10,418
+835
+9% +$62.7K ﹤0.01% 1947
2023
Q1 		$705K Buy
9,583
+1,087
+13% +$77.3K ﹤0.01% 1956
2022
Q4 		$568K Sell
8,496
-4,772
-36% -$310K ﹤0.01% 2078
2022
Q3 		$713K Buy
13,268
+2,058
+18% +$121K ﹤0.01% 1943
2022
Q2 		$624K Sell
11,210
-1,819
-14% -$103K ﹤0.01% 2124
2022
Q1 		$914K Buy
13,029
+1,003
+8% +$72.8K ﹤0.01% 2052
2021
Q4 		$1.16M Sell
12,026
-1,994
-14% -$184K ﹤0.01% 1951
2021
Q3 		$1.22M Sell
14,020
-994
-7% -$76.9K ﹤0.01% 1955
2021
Q2 		$1.23M Sell
15,014
-1,409
-9% -$117K ﹤0.01% 1983
2021
Q1 		$1.56M Sell
16,423
-85,877
-84% -$8.12M ﹤0.01% 1827
2020
Q4 		$6.35M Sell
102,300
-180,631
-64% -$10.3M ﹤0.01% 1414
2020
Q3 		$16.8M Sell
282,931
-191,724
-40% -$13.1M ﹤0.01% 1193
2020
Q2 		$33.1M Sell
474,655
-38,821
-8% -$2.46M ﹤0.01% 983
2020
Q1 		$23.3M Sell
513,476
-19,321
-4% -$1.1M ﹤0.01% 1019
2019
Q4 		$34.7M Sell
532,797
-14,603
-3% -$976K ﹤0.01% 1025
2019
Q3 		$34M Sell
547,400
-4,612
-0.8% -$290K ﹤0.01% 997
2019
Q2 		$39.3M Buy
552,012
+2,359
+0.4% +$174K 0.01% 964
2019
Q1 		$43.1M Buy
549,653
+11,858
+2% +$898K 0.01% 927
2018
Q4 		$45.5M Buy
537,795
+50,299
+10% +$5.36M 0.01% 862
2018
Q3 		$83.5M Buy
487,496
+20,916
+4% +$3.15M 0.01% 726
2018
Q2 		$60.3M Buy
466,580
+29,751
+7% +$3.32M 0.01% 819
2018
Q1 		$45M Buy
436,829
+23,040
+6% +$2.28M 0.01% 914
2017
Q4 		$35.3M Buy
413,789
+24,537
+6% +$2.13M 0.01% 1001
2017
Q3 		$33.1M Buy
389,252
+20,214
+5% +$1.6M 0.01% 1009
2017
Q2 		$27.9M Buy
369,038
+16,138
+5% +$1.13M 0.01% 1048
2017
Q1 		$23.3M Sell
352,900
-390,292
-53% -$25.7M ﹤0.01% 1093
2016
Q4 		$47.1M Sell
743,192
-97,128
-12% -$6.13M 0.01% 829
2016
Q3 		$53.5M Buy
840,320
+28,901
+4% +$2.12M 0.01% 782
2016
Q2 		$60.4M Buy
811,419
+24,461
+3% +$1.82M 0.01% 714
2016
Q1 		$52.6M Buy
786,958
+19,140
+2% +$1.16M 0.01% 755
2015
Q4 		$51.9M Buy
767,818
+22,843
+3% +$1.41M 0.01% 753
2015
Q3 		$39.8M Buy
744,975
+2,725
+0.4% +$165K 0.01% 857
2015
Q2 		$46.7M Buy
742,250
+588,301
+382% +$32.1M 0.01% 865
2015
Q1 		$7.41M Buy
153,949
+15,229
+11% +$583K ﹤0.01% 1404
2014
Q4 		$4.61M Sell
138,720
-9,779
-7% -$318K ﹤0.01% 1473
2014
Q3 		$4.35M Buy
148,499
+2,565
+2% +$85.1K ﹤0.01% 1477
2014
Q2 		$5.67M Buy
145,934
+16,030
+12% +$650K ﹤0.01% 1438
2014
Q1 		$5.45M Buy
129,904
+24,205
+23% +$1.01M ﹤0.01% 1422
2013
Q4 		$3.47M Buy
105,699
+89,448
+550% +$2.91M ﹤0.01% 1469
2013
Q3 		$439K Buy
16,251
+1,603
+11% +$45.1K ﹤0.01% 1938
2013
Q2 		$342K Buy
+14,648
New +$263K ﹤0.01% 2020

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

T. Rowe Price Associates's LGND Position: Q1 2026 in Review

T. Rowe Price Associates increased its Ligand Pharmaceuticals (LGND) stake by 20% in Q1 2026, buying an estimated $773K and bringing the position to 23,901 shares worth $4.77M. The position accounts for ﹤0.01% of the portfolio, ranked #1438.

T. Rowe Price Associates first reported a position in LGND in Q2 2013 and has held it in 52 quarters since. The position peaked at $83.5M in Q3 2018. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • T. Rowe Price Associates held 23,901 shares of Ligand Pharmaceuticals worth $4.77M as of Q1 2026.
  • T. Rowe Price Associates bought 3,909 Ligand Pharmaceuticals shares in Q1 2026, an estimated $773K.
  • Ligand Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1438 holding.
  • T. Rowe Price Associates first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • T. Rowe Price Associates's Ligand Pharmaceuticals position peaked at $83.5M in Q3 2018.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.